ANP Submits US Orphan Drug application for ATL1102 in DMD
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- EMA DMD Scientific Advice and Regulatory Process Update
- Trial Met Primary & Exceeded Secondary Endpoint Expectations
- Appointment of US-based Consultant Medical Director
- Results in DMD unlock value creation potential of ATL1102
- Quarterly Update & Appendix 4C
Later from Percheron Therapeutics
- ANP Submits EU Orphan Drug application for ATL1102 in DMD
- Antisense to present new data at WMS Virtual Congress 2020
- US FDA Grants RPDD to ATL1102 for the treatment of DMD
- ATL1102 shows significant improvement vs external control
- Pause in Trading
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics